Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma

scientific article published in May 2000

Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID10811107

P2093author name stringLo KW
Johnson PJ
Chan AT
Huang DP
Leung SF
Lo YM
Chan LY
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectadaptive radiation therapyQ180507
Epstein–Barr virusQ6900
P304page(s)2351-2355
P577publication date2000-05-01
P1433published inCancer ResearchQ326097
P1476titleKinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma
P478volume60

Reverse relations

cites work (P2860)
Q35121627A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer
Q37175573Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.
Q59350023Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
Q47136367Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer
Q46670174Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker
Q26750899Cell-free circulating tumor DNA in cancer
Q93105377Clinical value of a plasma Epstein-Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis
Q37325545Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology
Q40042999Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the IMRT Era: A Large-Scale Cohort Study
Q90075625Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study
Q33764579Current management strategy of nasopharyngeal carcinoma.
Q64899007Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Q52679757Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study.
Q45590622Evaluation of epstein-barr virus DNA load in gastric mucosa with chronic atrophic gastritis using a real-time quantitative PCR assay
Q90664639Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers
Q35087399Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma
Q37192117Laboratory assays for Epstein-Barr virus-related disease
Q36335515Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma
Q38385856Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).
Q21093175Nasopharyngeal carcinoma
Q92073973PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients
Q59382383Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients
Q34520470Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi
Q55234264Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma.
Q38270678Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma
Q36305182Positivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma
Q36073981Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.
Q90296660Prognostic Value of Plasma EBV DNA for Nasopharyngeal Cancer Patients during Treatment with Intensity-modulated Radiation Therapy and Concurrent Chemotherapy
Q99711993Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy
Q52647899Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.
Q58093740Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation
Q36962686Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma
Q33836183Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies
Q36892139The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers.
Q36152889The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases

Search more.